MedTrace Logo

Can Quantitative MRI After cTACE Help Predict Survival ?

NCT02173119 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2019-06-10

No results posted yet for this study

Summary

Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life. During TACE, a mixture of chemotherapy drugs is combined with an oil called lipiodol. Lipiodol has a role as both drug carrier and embolic agent (a material that blocks blood flow to tumors). The lipiodol/chemotherapy mixture is injected into an artery (blood vessel) directly supplying blood to a HCC tumor.

Lipiodol is made up of fat and water which can be seen on MRI. Therefore, MRI can be used to quantify the amount of lipiodol delivered to the HCC tumors.

In this study, the investigators want to see if patient survival is related to the amount of lipiodol delivered to HCC tumors.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

OTHER

MRI post-TACE

Perform lipiodol delivery measurements with MRI post-TACE.

Sponsors & Collaborators

Principal Investigators

  • Sarah B. White, MD · Medical College of Wisconsin

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2018-03-07
Completion
2018-03-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02173119 on ClinicalTrials.gov